Figure 1.

Therapeutic experiments for combination therapy of S-1 and docetaxel. Two previous studies have reported regimens of (A) docetaxel 40 mg m⁻² on day 1 with S-1 80 mg m⁻² for 2 weeks plus a 1-week rest, and (B) docetaxel 35 mg m⁻² on day 1 and 15 with S-1 80 mg m⁻² for 2 weeks plus a 2-week rest in patients with previously treated advanced NSCLC. The schedule employed in this study was (C) docetaxel 30–40 mg m⁻² on day 1 with S-1 80 mg m⁻² for 1 week, in which patients were treated by an anti-emetic treatment, plus a 1-week rest.